| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus. Glucose is used by cells in the brain to make energy that they need to live but glucose utilization may be impaired in the brain's of older people and especially those suffering from Senile Dementia or other forms of memory loss. There is growing evidence that this defective brain glucose utilization results from resistance to the action of insulin. Insulin sensitizer drugs such as Rosiglitazone and Pioglitazone help brain cells properly use glucose in individuals whose ability to use it is impaired. Several clinical studies have shown that these insulin sensitizer drugs improve learning and memory.
Dr. Daniel Chain, the Company's Founder & President and one of two inventors of the patent commented: "We are gratified that our seminal ideas concerning the ability of this class of drugs to combat Senile Dementia and other types of memory loss are being tested by GlaxoSmithKline, a major pharmaceutical company." Dr. Chain added: "We are hopeful that this new approach will help combat the devastating consequences of Senile Dementia and also help improve age-related memory loss affecting millions of older people who are not yet demented."
Professor Mike Cawthorne, Director of Metabolic Research, Clore Laboratory at The University of Buckingham (www.buckingham.ac.uk/clore) co-inventor with Dr. Chain and leader of the research team that originally discovered rosiglitazone as a diabetes treatment comme
'/>"/>
| SOURCE Mindset BioPharmaceuticals ( Copyright©2009 PR Newswire. All rights reserved |